Feb 3, 2026 04:05PM
Jan 20, 2026 04:05PM
Jan 20, 2026 09:01AM
Jan 20, 2026 09:00AM
Dec 10, 2025 03:55AM
Nov 13, 2025 04:05PM
Oct 28, 2025 09:01AM Aytu BioPharma receives patent extension for EXXUA through 2030
Oct 28, 2025 09:00AM
Sep 23, 2025 04:05PM
Jun 30, 2025 03:25AM
Jun 25, 2025 08:00AM
Jun 23, 2025 08:05AM
Jun 23, 2025 08:00AM
Jun 9, 2025 04:30PM Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opp
Jun 6, 2025 08:15AM
Jun 6, 2025 08:01AM
Jun 6, 2025 08:01AM
Jun 6, 2025 08:00AM
Oct 1, 2024 12:00PM
Oct 1, 2024 08:02AM
Nov 14, 2023 04:18PM Aytu BioScience (AYTU) Reports Q1 Revenue of $22.1M, Net Loss of $8.1M
Nov 14, 2023 04:05PM
Oct 26, 2023 08:05AM
Oct 26, 2023 08:00AM
Sep 27, 2023 04:22PM
Sep 26, 2023 08:27PM
Jul 10, 2023 08:02AM
Jul 10, 2023 08:00AM Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
May 11, 2023 04:05PM
May 1, 2023 08:02AM
May 1, 2023 08:00AM
Apr 27, 2023 08:01AM
Apr 27, 2023 08:00AM
Jan 10, 2023 08:03AM
Jan 10, 2023 08:00AM Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Nov 30, 2022 08:00AM
Oct 5, 2022 08:02AM
Oct 5, 2022 08:00AM
Sep 27, 2022 04:05PM
Sep 20, 2022 08:00AM
Sep 14, 2022 08:04AM
Sep 14, 2022 08:00AM Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
Aug 24, 2022 08:00AM
Aug 16, 2022 08:04AM
Aug 16, 2022 08:00AM
Aug 15, 2022 04:01PM
Aug 9, 2022 09:17AM
Aug 9, 2022 09:15AM
Aug 8, 2022 04:02PM Aytu BioScience (AYTU) Announces Public Offering
Aug 8, 2022 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All